Product Information
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB is a generic product labeled by BluePoint Laboratories, priced at $0.0969 per EA under NDC 68001032703. Its NADAC has been published 431 times since Aug 2, 2017.
FDA first approved this application on Apr 17, 1988. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 37.5 mg/1; mg/1
Manufacturer
BluePoint LaboratoriesNDC
68001032703
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; TRIAMTERENEApproval Type
Generic (ANDA)
FDA Application
ANDA071251FDA Approved
4/17/1988
TE Code
AB
On Market Since
4/30/2017
Pharmacological Classes
Price Statistics
The NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB has been published 431 times since Aug 2, 2017, and over the history we have for it it has declined 18.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0969 per EA |
|---|---|
| All-time high | $0.1409 (Aug 15, 2018) |
| All-time low | $0.0721 (Nov 20, 2024) |
| 52-week high | $0.0983 |
| 52-week low | $0.0915 |
| Median price | $0.0983 |
| Average price | $0.1036 |
| Largest weekly change | -29.0% (Nov 20, 2024) |
| Weeks tracked | 431 |
| Tracking since | Aug 2, 2017 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
BluePoint Laboratories manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Triamterene and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Potassium-sparing Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB, manufactured by BluePoint Laboratories, is $0.0969 per EA (NDC 68001032703), effective Sep 30, 2026.
How has the price of TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB changed over time?
Over the history we have for it, the NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB has declined 18.6%. It has been tracked across 431 weekly CMS publications since Aug 2, 2017.
What are the highest and lowest recorded NADAC prices for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB?
Since Aug 2, 2017, the NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB has ranged from a low of $0.0721 (Nov 20, 2024) to a high of $0.1409 (Aug 15, 2018), with a median of $0.0983 per EA.
Are there cheaper alternatives to TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB, is $0.0963 per EA — about 1% below TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB.
Who manufactures TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB?
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB (NDC 68001032703) is labeled by BluePoint Laboratories, and CMS classifies it as a generic product.